NAUT vs. AKYA, SEER, BCAB, PACB, ORIC, TALS, AFMD, QTRX, EYPT, and VBIV
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Akoya Biosciences (AKYA), Seer (SEER), BioAtla (BCAB), Pacific Biosciences of California (PACB), ORIC Pharmaceuticals (ORIC), Talaris Therapeutics (TALS), Affimed (AFMD), Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), and VBI Vaccines (VBIV). These companies are all part of the "medical" sector.
Akoya Biosciences (NASDAQ:AKYA) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation.
Akoya Biosciences has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.
Akoya Biosciences has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Akoya Biosciences, indicating that it is currently the more affordable of the two stocks.
Nautilus Biotechnology has a net margin of 0.00% compared to Nautilus Biotechnology's net margin of -72.68%. Akoya Biosciences' return on equity of -24.94% beat Nautilus Biotechnology's return on equity.
79.4% of Akoya Biosciences shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 7.3% of Akoya Biosciences shares are held by company insiders. Comparatively, 42.5% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Akoya Biosciences received 25 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 16.67% of users gave Nautilus Biotechnology an outperform vote.
In the previous week, Akoya Biosciences had 20 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 20 mentions for Akoya Biosciences and 0 mentions for Nautilus Biotechnology. Akoya Biosciences' average media sentiment score of 0.00 beat Nautilus Biotechnology's score of -0.56 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.
Akoya Biosciences currently has a consensus target price of $7.79, suggesting a potential upside of 173.18%. Nautilus Biotechnology has a consensus target price of $6.00, suggesting a potential upside of 103.39%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe Akoya Biosciences is more favorable than Nautilus Biotechnology.
Summary
Akoya Biosciences beats Nautilus Biotechnology on 11 of the 17 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Nautilus Biotechnology Competitors List
Related Companies and Tools